Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques (original) (raw)

• Palella, F.J. Jr. et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N. Engl. J. Med. 338, 853–860 (1998).
  Article PubMed Google Scholar
• Finzi, D. et al. Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278, 1295–1300 (1997).
  Article CAS PubMed Google Scholar
• Wong, J.K. et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278, 1291– 1295 (1997).
  Article CAS PubMed Google Scholar
• Davey, R.T. Jr. et al. HIV-1 and T cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc. Natl Acad. Sci. USA 96, 15109–15114 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Lisziewicz, J. et al. Control of HIV despite the discontinuation of antiretroviral therapy. N. Engl. J. Med. 340, 1683– 1684 (1999).
  Article CAS PubMed Google Scholar
• Ortiz, G.M. et al. HIV-1-specific immune responses in subjects who temporarily contain virus replication after discontinuation of highly active antiretroviral therapy. J. Clin. Invest. 104, R13– R18 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Borrow, P., Lewicki, H., Hahn, B.H., Shaw, G.M. & Oldstone, M.B. A. Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J. Virol. 68, 6103 –6110 (1994).
  CAS PubMed PubMed Central Google Scholar
• Koup, R.A. et al. Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome . J. Virol. 68, 4650–4655 (1994).
  CAS PubMed PubMed Central Google Scholar
• Nixon, D.F. et al. HIV-1 Gag-specific cytotoxic T lymphocytes defined with recombinant vaccinia virus and synthetic peptides. Nature 336, 484–487 (1988).
  Article CAS PubMed Google Scholar
• Pantaleo, G. et al. Major expansion of CD8+ T cells with a predominant V beta usage during the primary immune response to HIV. Nature 370, 463–467 (1994).
  Article CAS PubMed Google Scholar
• Rinaldo, C. et al. High levels of anti-human immunodeficiency virus type 1 (HIV-1) memory cytotoxic T-lymphocyte activity and low viral load are associated with lack of disease in HIV-1-infected long-term nonprogressors. J. Virol. 69, 5838–5842 ( 1995).
  CAS PubMed PubMed Central Google Scholar
• Autran, B. et al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277, 112–116 ( 1997).
  Article CAS PubMed Google Scholar
• Oxenius, A. et al. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc. Natl Acad. Sci. USA 97, 3382– 3387 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Rosenberg, E.S. et al. Vigorous HIV-1-specific CD4+ t cell responses associated with control of viremia. Science 278, 1447– 1450 (1997).
  Article CAS PubMed Google Scholar
• Gray, C.M. et al. Frequency of class I HLA-restricted anti-HIV CD8+ T cells in individuals receiving highly active antiretroviral therapy (HAART). J. Immunol. 162, 1780–1788 (1999).
  CAS PubMed Google Scholar
• Morris, L. et al. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J. Exp. Med. 188, 233–245 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Ogg, G.S. et al. Decay kinetics of human immunodeficiency virus-specific effector cytotoxic T lymphocytes after combination antiretroviral therapy. J. Virol. 73, 797–800 ( 1999).
  CAS PubMed PubMed Central Google Scholar
• Benson, J. et al. Recombinant vaccine-induced protection against the highly pathogenic SIV mac251: dependence on route of challenge exposure . J. Virol. 72, 4170–4182 (1998).
  CAS PubMed PubMed Central Google Scholar
• Evans, T.G. et al. A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J. Infect. Dis. 180, 290–298 (1999).
  Article CAS PubMed Google Scholar
• Hanke, T. et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus ankara boost vaccination regimen. J. Virol. 73, 7524–7532 (1999).
  CAS PubMed PubMed Central Google Scholar
• Seth, A. et al. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J. Virol. 74, 2502– 2509 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Franchini, G. et al. Highly attenuated HIV type 2 recombinant poxviruses, but not HIV-2 recombinant Salmonella vaccines, induce long-lasting protection in rhesus macaques. AIDS Res. Hum. Retroviruses 11, 909–920 (1995).
  Article CAS PubMed Google Scholar
• Klein, J. et al. Nomenclature for the major histocompatibility complexes of different species: a proposal. Immunogenetics 31, 217–219 (1990).
  CAS PubMed Google Scholar
• Knapp, L.A., Lehmann, E., Piekarczyk, M.S., Urvater, J.A. & Watkins, D.I. A high frequency of Mamu-A*01 in the rhesus macaque detected by PCR-SSP and direct sequencing. Tissue Antigens 50, 657–661 (1997).
  Article CAS PubMed Google Scholar
• Allen, T.M. et al. Characterization of the peptide binding motif of a rhesus MHC class I molecule (Mamu-A*01) that binds an immunodominant CTL epitope from simian immunodeficiency virus. J. Immunol. 160, 6062–6071 (1998).
  CAS PubMed Google Scholar
• Miller, M.D., Yamamoto, H., Hughes, A.L., Watkins, D.I. & Letvin, N.L. Definition of an epitope and MHC class I molecule recognized by gag-specific cytotoxic T lymphocytes in SIVmac-infected rhesus monkeys. J. Immunol. 147, 320–329 (1991).
  CAS PubMed Google Scholar
• Franchini, G. et al. Sequence of simian immunodeficiency virus and its relationship to the human immunodeficiency viruses. Nature 328, 539–543 (1987).
  Article CAS PubMed Google Scholar
• Letvin, N.L. et al. The CD8+ T lymphocyte response during primary SIVmac infection . Adv. Exp. Med. Biol. 452, 177– 179 (1998).
  Article CAS PubMed Google Scholar
• Binley, J.M. et al. The relationship between T cell proliferative responses and plasma viremia during treatment of human immunodeficiency virus type 1 infection with combination antiretroviral therapy. J. Infect. Dis. 181, 1249–1263 (2000).
  Article CAS PubMed Google Scholar
• Haslett, P.A. et al. Strong human immunodeficiency virus (HIV)-specific CD4+ T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy. J. Infect. Dis. 181, 1264–1272 (2000).
  Article CAS PubMed Google Scholar
• Herbein, G. et al. Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp120 with chemokine receptor CXCR4. Nature 395, 189–194 ( 1998).
  Article CAS PubMed Google Scholar
• Li, C.J., Friedman, D.J., Wang, C., Metelev, V. & Pardee, A.B. Induction of apoptosis in uninfected lymphocytes by HIV-1. Science 268, 429– 431 (1995).
  Article CAS PubMed Google Scholar
• Westendorp, M.O. et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 . Nature 375, 497–500 (1995).
  Article CAS PubMed Google Scholar
• Pitcher, C.J. et al. HIV-1-specific CD4+ T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression . Nature Med. 5, 518–525 (1999).
  Article CAS PubMed Google Scholar
• Yasutomi, Y. et al. A vaccine-elicited, single viral epitope-specific cytotoxic T lymphocyte response does not protect against intravenous, cell-free simian immunodeficiency virus challenge. J. Virol. 69, 2279–2284 (1995).
  CAS PubMed PubMed Central Google Scholar
• Allen, T.M. et al. Acute viral escape from cytotoxic T lymphocytes: implications for HIV vaccine design. Nature (in press).
• Tsai, C.-C. et al. Prevention of simian immunodeficiency virus infection in macaques by 9-(2-phosphonylmethoxypropyl) adenine (PMPA). Science 270, 1197–1199 (1995).
  Article CAS PubMed Google Scholar
• Tartaglia, J. et al. NYVAC: a highly attenuated strain of vaccinia virus. Virology 188, 217–232 ( 1992).
  Article CAS PubMed Google Scholar
• Barouch, D.H. et al. Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. Proc. Natl Acad. Sci. USA 97, 4192– 4197 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Jacobson, E.L., Pilaro, F. & Smith, K.A. Rational interleukin 2 therapy for HIV positive individuals: daily low doses enhance immune function without toxicity . Proc. Natl Acad. Sci. USA 93, 10405– 10410 (1996).
  Article CAS PubMed PubMed Central Google Scholar
• Kovacs, J.A. et al. Controlled trial of interleukin-2 infusions in patients infected with the human immunodeficiency virus. N. Engl. J. Med. 335, 1350–1356 (1996).
  Article CAS PubMed Google Scholar
• Romano, J.W., Williams, K.G., Shurtliff, R.N., Ginocchio, C. & Kaplan, M. NASBA technology: isothermal RNA amplification in qualitative and quantitative diagnostics. Immunol. Invest. 26, 15–28 (1997).
  Article CAS PubMed Google Scholar